Research Article
Active Learning and the Potential of Neural Networks Accelerate Molecular Screening for the Design of a New Molecule Effective against SARS-CoV-2
Table 2
Selected drug information of current ongoing clinical studies on SARS-CoV-2.
| Drug name | Mechanism of action | Indication | DrugBank ID |
| Remdesivir | RNA polymerase inhibitor | Anti-Ebola passed phase III, COVID-19 phase III | DB14761 | Lopinavir | Protease inhibitor | Anti-HIV approved, COVID-19 | DB01601 | Ritonavir | Protease inhibitor | Anti-HIV approved, COVID-19 | DB00503 | Emtricitabine | Nucleoside reverse transcriptase inhibitor | Anti-HIV approved, anti-HBV | DB00879 | Tenofovir | Nucleoside reverse transcriptase inhibitor | Anti-HIV phase III, anti-HBV | DB14126 | Ribavirin | Viral mRNA and protein synthesis inhibitor | Anti-HCV, anti-HBV, anti-SARS, anti-influenza, COVID-19 | DB00811 | Methylprednisolone | Corticosteroid | COVID-19 phase II, allergic asthma and rheumatic disorders approved | DB00959 | Oseltamivir | Neuraminidase inhibitor; sialidase inhibitor | Anti-influenza approved, COVID-19 phase III | DB00198 | Danoprevir | Protease inhibitor | Anti-HCV phase III, COVID-19 phase 4 | DB11779 | Chloroquine | ā | Antimalarial approved, anti-HIV phase III, anti-HCV, COVID-19 phase 4 | DB14761 |
|
|